Specialty Guide · Path-iQ Global Pathology Review
Surgical pathology is the largest and most clinically impactful subspecialty in diagnostic pathology. Every surgical resection, biopsy, and excision specimen that reaches the laboratory must be accurately grossed, processed, and interpreted to guide patient management. This guide covers specimen handling, key techniques, subspecialty niches, and the leading practitioners defining the field in 2026.
Surgical pathology is the branch of anatomic pathology concerned with the macroscopic and microscopic examination of tissues removed from living patients by surgical procedures — biopsies, endoscopic resections, excisions, and radical resections. The surgical pathologist renders a definitive tissue diagnosis that determines whether a tumour is benign or malignant, the histological type and grade, the adequacy of surgical margins, and the stage of disease.
Unlike cytopathology (which examines individual cells) or autopsy pathology (post-mortem examination), surgical pathology works with intact tissue architecture — the arrangement of cells within stroma, the integrity of basement membranes, and the relationship of neoplastic cells to blood vessels and nerves. This architectural information is often the most critical determinant of diagnosis and prognosis.
| Specimen Type | Examples | Key Gross Steps | Critical Measurements |
|---|---|---|---|
| Core needle biopsy | Prostate, breast, liver, kidney, lung | Count cores, measure length, section transversely | Core length (mm), number of cores |
| Punch biopsy | Skin, mucosa | Bisect or trisect perpendicular to surface | Diameter (mm), depth |
| Excisional biopsy | Lymph node, skin lesion | Ink margins, serial section | Dimensions, distance from margins |
| Wide local excision | Breast lumpectomy, soft tissue tumour | Ink all surfaces by colour code, breadloaf sections | 6-surface margin distances (mm) |
| Endoscopic resection | EMR/ESD colon, oesophagus, stomach | Pin flat, photograph, serial perpendicular sections | Tumour size, SM depth of invasion (µm) |
| Radical resection | Whipple, radical cystectomy, TME | Fresh or fixed, paint margins, standardised sections | CRM, tumour-to-margin distance, LN count |
| Sentinel lymph node | Breast, melanoma, endometrial cancer | Serial sections at 2 mm intervals; IHC if H&E negative | ITCs (<0.2 mm) vs micromet (0.2–2 mm) vs macrometastasis |
| Intraoperative consultation | Frozen section, smear, touch prep | Immediate cryostat sections; verbal report ≤20 min | Margin status, tumour type, lymph node involvement |
Frozen section (FS) is the most time-critical task in surgical pathology. The surgeon submits fresh tissue to the pathologist while the patient is under anaesthesia; the pathologist cuts cryostat sections (4–6 µm), stains with H&E, and provides a preliminary diagnosis — typically within 15–20 minutes.
Frozen section accuracy exceeds 98% for most common applications. Deferred diagnoses ("await permanent sections") are appropriate for small lesions, fatty specimens, bony tissue, and when the frozen result may not change intraoperative management.
Surgical margin status is one of the most actionable findings in surgical pathology — a positive margin typically leads to re-excision or adjuvant radiotherapy. Yet margin reporting lacks global standardisation and remains a common source of clinical confusion.
| Organ / Tumour | Positive Margin Threshold | Reporting Standard | Clinical Impact |
|---|---|---|---|
| Breast invasive carcinoma (BCS) | Ink on tumour (SSO/ASTRO 2014) | Distance to nearest inked margin (mm) | Re-excision if ink on tumour; RT covers close margins |
| Breast DCIS | <2 mm (SSO/ASTRO 2016) | Distance to all inked margins | Re-excision for <2 mm; 2+ mm adequate with RT |
| Prostate (radical prostatectomy) | Tumour at inked surface | Linear extent of positive margin (mm) | PSM associated with biochemical recurrence; adjuvant RT considered |
| Colorectal cancer | CRM ≤1 mm (rectal); distal <1 cm | Distance to circumferential resection margin | CRM positivity — major predictor of local recurrence in rectal cancer |
| Oral cavity SCC | <5 mm (clear >5 mm) | Distance to nearest mucosal or deep margin | Re-excision or adjuvant RT for close/positive margins |
| Soft tissue sarcoma | Ink on tumour | Minimum margin distance; note proximity to fascial planes | Re-excision for R1; adjuvant RT commonly used for close margins |
| Pancreatic cancer (Whipple) | R1 = tumour ≤1 mm (Leeds protocol) | Distance to each named margin: anterior, posterior, SMA, SMV groove, bile duct, pancreatic neck | R1 predicts poor OS; SMV/SMA margin most critical |
| Melanoma (WLE) | Protocol-dependent (1–2 cm clinical) | Pathological margin distance (mm); note if tumour at deep fascia | Re-excision per guidelines based on Breslow depth |
Largest subspecialty by volume. Includes Barrett's oesophagus surveillance, gastric cancer Lauren classification, colorectal cancer staging, IBD grading, and endoscopic resection assessment. Molecular testing (MSI, KRAS, HER2) now integral to GI pathology reports.
Encompasses core biopsy, excision, sentinel node, and mastectomy specimens. Biomarker reporting (ER, PR, HER2, Ki-67) directly drives systemic therapy decisions. HER2-low detection and ESR1 mutation testing are emerging priorities in 2026.
Prostate cancer Gleason/ISUP grading, bladder cancer stage and grade, renal cell carcinoma subtyping, and testicular tumour classification. MRI-guided prostate biopsy has changed specimen types and reporting requirements significantly.
HPV-associated cervical neoplasia, endometrial carcinoma molecular classification (POLE, MMR, p53), ovarian carcinoma histotyping, and vulvar SCC subtypes. FIGO 2023 staging changes require updated reporting templates.
WHO CNS5 (2021) mandates molecular integration — IDH mutation, 1p/19q codeletion, TERT promoter, CDKN2A/B deletion, EGFR amplification — into glioma classification. Intraoperative smear cytology and frozen section remain critical for surgical decision-making.
HPV status in oropharyngeal SCC by p16 IHC and ISH; thyroid carcinoma WHO 2022 revisions including NIFTP; salivary gland tumour molecular classification (MYB, MAML2, NR4A3 fusions); sinonasal undifferentiated carcinoma workup.
High complexity, low volume — sarcoma diagnosis requires clinical, radiological, and pathological integration. FISH and RNA-based NGS for translocation detection (SS18-SSX, EWSR1, MDM2) are now standard. Expert centre review recommended for all sarcomas.
Thyroid carcinoma variants per WHO 2022, adrenal cortical tumour Weiss scoring, phaeochromocytoma PASS and GAPP scores, pituitary adenoma (now "pituitary neuroendocrine tumour") transcription factor classification.
Synoptic (checklist-based) reporting has replaced narrative-only reports in most high-income countries. The College of American Pathologists (CAP) publishes mandatory data element protocols for all major tumour sites, updated following each WHO Classification revision. UK RCPath and European ICCR produce equivalent templates.
A complete synoptic report includes: specimen type and procedure, tumour site and laterality, histological type per current WHO, grade, tumour size (greatest dimension and additional dimensions), pathological stage (pTNM), margin status, lymphovascular invasion, perineural invasion, lymph node status (number positive / number examined), and all applicable biomarkers. Mandatory elements must be completed; conditional elements depend on the specific tumour type and stage.
AI-assisted tools are entering surgical pathology for quantitative tasks that are reproducible but time-consuming: Ki-67 quantification in neuroendocrine tumours, HER2 scoring standardisation, tumour-infiltrating lymphocyte (TIL) scoring, Gleason grading support, and mitotic figure detection. Paige Prostate (FDA-cleared 2021) was the first AI tool cleared for primary diagnosis in surgical pathology. Additional tools from PathAI, Ibex, and Aiforia are in various stages of regulatory review for specific applications.
World authority on pancreatic neoplasms, GI neuroendocrine tumours, and ampullary carcinoma. Led multiple WHO Classification working groups on digestive system tumours.
Internationally recognised for breast pathology and gynaecological neoplasms. Former co-editor of the WHO Classification of Breast Tumours and Tumours of the Female Genital Organs.
Architect of the current Gleason grading system (modified Gleason and ISUP grade groups). Author of Epstein's Biopsy Interpretation of the Prostate, the field's standard text.
Leading Australasian soft tissue and bone tumour pathologist; contributor to ICCR dataset development for sarcomas and the Australian sarcoma expert review network.
Expert in endometrial carcinoma molecular classification, uterine smooth muscle tumour diagnosis, and the emerging MELF pattern of invasion in endometrial cancer.
Expert in colorectal carcinoma staging, TME quality grading, and the pathology of Lynch syndrome-associated colorectal cancers.